Top Suppliers:I want be here
Related CAS#:
190977-41-4 61618-27-7
1192491-61-4 69388-84-7
16482-55-6 30605-57-3
61538-65-6 54600-91-8
88911-12-0 54807-39-5
1806941-81-0 1805157-59-8
1807121-68-1 1807214-44-3
1823254-23-4 1824306-38-8
1822826-42-5 1823544-64-4
1893405-25-8 1805341-51-8

190977-41-4

190977-41-4 structure
190977-41-4 structure
  • Name: Oblimersen sodium
  • Chemical Name: Oblimersen sodium
  • CAS Number: 190977-41-4
  • Molecular Formula: C172H204N62Na17O91P17S17
  • Molecular Weight:
  • Catalog: Signaling Pathways Apoptosis Apoptosis
  • Create Date: 2018-06-08 14:01:46
  • Modify Date: 2025-08-25 11:37:49
  • Oblimersen is a BCL-2 inhibitor targeting BCL-2 RNA. Oblimersen specifically binds to the first six codons of the bcl-2 mRNA sequence, resulting in degradation of bcl-2 mRNA and induces apoptosis by down-regulating expression of Bcl-2. Oblimersen can be used for cancer research[1][2][3].
Name Oblimersen sodium
Synonyms GENASENSE
Oblimersen sodium
Description Oblimersen is a BCL-2 inhibitor targeting BCL-2 RNA. Oblimersen specifically binds to the first six codons of the bcl-2 mRNA sequence, resulting in degradation of bcl-2 mRNA and induces apoptosis by down-regulating expression of Bcl-2. Oblimersen can be used for cancer research[1][2][3].
Related Catalog
In Vitro Oblimersen (500 nM; 72 hours; human small-cell lung cancer cell lines H69) decreases BCL-2 protein expression in vitro[1]. Oblimersen (500 nM; 72 hours; human small-cell lung cancer cell lines H69) increases radiation-induced apoptosis[1]. Cell Cycle Analysis[1] Cell Line: Human small-cell lung cancer cell lines H69 Concentration: 500 nM Incubation Time: 72 hours Result: Decreased BCL-2 protein levels. Cell Cycle Analysis[1] Cell Line: Human small-cell lung cancer cell lines H69 Concentration: 500 nM Incubation Time: 72 hours Result: Arrested cell cycle at sub G1 phase.
In Vivo Oblimersen (10 mg/kg; i.p.; daily, for 6 days; nude mice bearing H69 xenografts) decreases tumoural vascularisation in vivo[1]. Oblimersen (5-10 mg/kg; i.p.; daily (Monday to Friday), for 3 weeks) has antitumor efficacy in the subcutaneous tumor model[2]. Animal Model: Male severe combined immunodeficient (SCID)-RAG2 mice[2] Dosage: 5 and 10 mg/kg Administration: Intraperitoneal injection; daily (Monday to Friday), for 3 weeks Result: Inhibited tumor growth in a dose-dependent manner.
References

[1]. Loriot Y, et, al. Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response. Anticancer Res. 2010 Oct;30(10):3869-78.

[2]. Hu Y, et, al. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer. Clin Cancer Res. 2004 Nov 15;10(22):7662-70.

[3]. Klasa RJ, et, al. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):193-213.
Molecular Formula C172H204N62Na17O91P17S17
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Chemsrc provides CAS#:190977-41-4 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 190977-41-4 | Chemsrc address: https://m.chemsrc.com/en/baike/1516574.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved